NLRP3 Inhibitor/Nrf2 Upregulator Receives FDA FTD for Severe Oral Mucositis
Cancer Network,
The FDA accepted an investigational new drug application (IND) for and granted fast track designation to RRx-001, a direct…
The FDA accepted an investigational new drug application (IND) for and granted fast track designation to RRx-001, a direct…
Tony Reid, MD, PhD The FDA has granted a fast track designation to RRx-001 for the prevention and attenuation of severe oral…
Oral mucositis is a side effect of radiation therapy to the head and neck. Symptoms of oral mucositis include dry mouth, thick…
Oral mucositis is a side effect of radiation therapy to the head and neck. Symptoms of oral mucositis include dry mouth, thick…